IDH1 and neoplasm: Independent of the tumor grade, we also found a dramatic increase in survival in patients presenting IDH1 mutation (29.2 months), suggesting that this gene is an important biomarker, as the authors have previously found that IDH mutation was the main driver of the clusters (Ceccarelli et al. 2016).